一身白大褂，一边耐心询问村民的血压情况，一边在笔记本上记录基层诊疗中的所思所想——在福建不 少地方的县医院、基层卫生院，经常能看到全国政协委员、福建省高血压研究所所长谢良地的身影。对 他来说，这既是临床工作，也是作为政协委员的职责。 "硬件有了，人员也在，但专业能力和系统性还远远不够。"他坦言，基层医生往往"全科都管"，难以在 高血压等慢病防治上做专做细。为此，谢良地推动建立省、市、县三级高血压防控网络，通过"传帮 带"层层培训，让优质资源下沉，让基层医生有更系统的学习机会。 在谢良地看来，高血压的"防"比"治"更重要。几年前，他就建议将健康生活方式教育纳入小学教材，推 动在医疗机构、机场、车站等公共场所设置自助血压测量设备。"许多患者直到出现高血压并发症才就 医，往往为时已晚。早发现、早干预，才能真正减轻家庭和社会负担。"谢良地说。 作为医卫界政协委员，谢良地今年将围绕"加强慢病防控基层建设"提出建议，涵盖政策协同、资源下 沉、中西医并重、人才培养等多方面。"慢病管理是一场持久战，需要政府、医院、媒体、公众等力量 共同参与。"谢良地说，自己的角色就像一名"桥梁工"——连接政策与落实、专业与普及、治疗与预 防 ...

提出高质量提案，关键在深入调查研究。谢良地来自闽东山村，乡村始终是他关注的焦点，每年他有近三分之一的时间奔走在基层。 一身白大褂，一边耐心询问村民的血压情况，一边在笔记本上记录基层诊疗中的所思所想——在福建不少地方的县医院、基层卫生院，经常能看到全国政协 委员、福建省高血压研究所所长谢良地的身影。对他来说，这既是临床工作，也是作为政协委员的职责。 "高血压不是孤立的疾病，它是一种生活方式病。"谢良地说。我国高血压患者基数庞大，但高血压的知晓率、治疗率、控制率相对较低。作为一名从事高血 压防治工作数十年的临床医生，他的履职工作始终围绕"如何让更多人远离高血压"展开。 在2025年全国两会上，谢良地呼吁为高血压防控打造专业平台，培养专职队伍。"没有专科，医生就没有'阵地'；没有专业队伍，防控就难成体系。"在他看 来，高血压防治涉及预防、筛查、诊断、治疗、康复等多个环节，必须有一支专业的队伍"盯得住、管得全"。 2025 年世界高血压日，福建省高血压研究所所长谢良地为群众义诊。（受访者供图） 基于对基层情况的深入了解，谢良地将履职的着力点放在如何织密慢病防控这张网上。一年来，谢良地走进南平浦城、宁德周宁、龙岩上杭等 ...

一身白大褂，一边耐心询问村民的血压情况，一边在笔记本上记录基层诊疗中的所思所想——在福建不 少地方的县医院、基层卫生院，经常能看到全国政协委员、福建省高血压研究所所长谢良地的身影。对 他来说，这既是临床工作，也是作为政协委员的职责。 ●新华社记者 黄景鸿 吴剑锋 作为医卫界政协委员，谢良地今年将围绕"加强慢病防控基层建设"提出建议，涵盖政策协同、资源下 沉、中西医并重、人才培养等多方面。"慢病管理是一场持久战，需要政府、医院、媒体、公众等力量 共同参与。"谢良地说，自己的角色就像一名"桥梁工"——连接政策与落实、专业与普及、治疗与预 防。 "让更多人知晓高血压、防控高血压，这件事本身就是在为国家减负、为家庭造福。"谢良地说，作为医 生和政协委员，他最大的心愿，就是通过一点一滴的努力，把慢病防控的"网"织得更密、更牢。 【记者手记】 采访谢良地委员，印象最深的是他话语中那份"接地气"的务实。他不仅是高血压防治领域的专家，更是 长期扎根一线的观察者与行动者。他的履职，始终围绕"问题从哪里来，就到哪里去找答案"——门诊、 基层卫生院、患者家中，都是他的调研现场。 "高血压不是孤立的疾病，它是一种生活方式病。"谢良地 ...

Core Viewpoint - Yipinhong's stock price has shown a slight increase of 0.18% year-to-date, but has experienced significant declines over various time frames, indicating potential volatility in the stock performance [2]. Group 1: Stock Performance - On February 3, Yipinhong's stock rose by 2.00%, reaching a price of 33.61 CNY per share, with a trading volume of 1.24 billion CNY and a turnover rate of 0.89%, resulting in a total market capitalization of 15.181 billion CNY [1]. - The stock has decreased by 5.03% over the last five trading days, 6.35% over the last 20 days, and 31.24% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Yipinhong reported a revenue of 814 million CNY, reflecting a year-on-year decrease of 34.35%, while the net profit attributable to shareholders was -136 million CNY, showing a year-on-year increase of 44.80% [2]. - Since its A-share listing, Yipinhong has distributed a total of 335 million CNY in dividends, with 151 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of January 31, the number of Yipinhong's shareholders reached 30,500, an increase of 14.93% from the previous period, with an average of 13,705 circulating shares per shareholder, a decrease of 12.99% [2]. - Notable new shareholders include Hong Kong Central Clearing Limited, holding 4.1496 million shares, and several mutual funds entering the top ten circulating shareholders [3].

Core Viewpoint - The stock price of Xinlitai has shown a year-to-date increase of 7.75%, with a recent trading performance indicating fluctuations in the short term, reflecting both growth and volatility in the pharmaceutical sector [2]. Group 1: Stock Performance - As of January 15, Xinlitai's stock price rose by 2.06% to 53.39 CNY per share, with a trading volume of 1.15 billion CNY and a turnover rate of 0.20%, resulting in a total market capitalization of 59.52 billion CNY [1]. - Year-to-date, Xinlitai's stock has increased by 7.75%, with a slight rise of 0.53% over the last five trading days, but a decline of 4.98% over the past 20 days and 4.83% over the last 60 days [2]. Group 2: Company Overview - Xinlitai, established on November 3, 1998, and listed on September 10, 2009, is located in Shenzhen, Guangdong Province. The company specializes in the research, production, and sales of pharmaceuticals and medical devices [2]. - The revenue composition of Xinlitai includes 81.69% from formulations, 8.54% from medical devices, 7.17% from raw materials, and 2.59% from other sources [2]. - Xinlitai operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concept segments such as hypertension treatment, anti-cancer drugs, and generic drugs [2]. Group 3: Financial Performance - For the period from January to September 2025, Xinlitai reported a revenue of 3.241 billion CNY, reflecting an 8.00% year-on-year growth, while the net profit attributable to shareholders reached 581 million CNY, marking a 13.93% increase [2]. - Since its A-share listing, Xinlitai has distributed a total of 7.204 billion CNY in dividends, with 1.649 billion CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, 2025, Xinlitai had 25,200 shareholders, an increase of 4.87% from the previous period, with an average of 44,249 circulating shares per shareholder, down by 4.64% [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, while Industrial Bank Frontier Medical Stock A saw a reduction in holdings [3].

Group 1 - The core viewpoint of the news is that Enhua Pharmaceutical's stock has shown a slight increase in price, with a current trading value of 24.64 yuan per share and a total market capitalization of 250.29 billion yuan [1] - As of January 9, the stock price has increased by 2.11% year-to-date, with a 5-day increase of 2.11%, a 20-day increase of 0.53%, and a 60-day decrease of 5.16% [1] - The company is primarily engaged in pharmaceutical production, research, and sales, with its main revenue sources being anesthetics (54.28%), psychotropic drugs (20.63%), and commercial pharmaceuticals (13.08%) [1] Group 2 - As of September 30, the company reported a revenue of 4.471 billion yuan for the first nine months of 2025, representing a year-on-year growth of 7.85%, and a net profit attributable to shareholders of 1.106 billion yuan, up 8.42% year-on-year [2] - The company has distributed a total of 1.577 billion yuan in dividends since its A-share listing, with 890 million yuan distributed over the past three years [3] - The number of shareholders decreased by 14.20% to 37,400, while the average circulating shares per person increased by 16.85% to 23,614 shares [2]

Group 1 - The core viewpoint of the news is that Yipin Hong's stock has shown volatility with a recent increase in price, but the company faces challenges in revenue and profit margins [1][2]. - As of January 9, Yipin Hong's stock price increased by 2.11% to 36.78 CNY per share, with a total market capitalization of 16.613 billion CNY [1]. - The company has experienced a 9.63% increase in stock price year-to-date, but a significant decline of 33.88% over the past 60 days [1]. Group 2 - For the fiscal year ending December 31, Yipin Hong reported a revenue of 814 million CNY, a decrease of 34.35% year-on-year, while the net profit attributable to shareholders was -136 million CNY, reflecting a growth of 44.80% [2]. - The company has distributed a total of 335 million CNY in dividends since its A-share listing, with 151 million CNY distributed over the past three years [3]. - As of September 30, 2025, Yipin Hong's shareholder count increased by 30.22% to 26,500, while the average circulating shares per person decreased by 23.21% to 15,750 shares [2].

Group 1 - The core viewpoint of the news is that 海思科 has shown a mixed performance in stock price and financial results, with a notable increase in stock price recently but a decline in net profit year-on-year [1][2]. Group 2 - As of January 9, 海思科's stock price increased by 2.09% to 56.15 CNY per share, with a total market capitalization of 628.83 billion CNY [1]. - The company has seen a year-to-date stock price increase of 9.41%, with a 9.41% rise over the last five trading days, a 3.98% decline over the last 20 days, and an 8.13% increase over the last 60 days [1]. - For the period from January to September 2025, 海思科 reported a revenue of 3.3 billion CNY, representing a year-on-year growth of 19.95%, while the net profit attributable to shareholders decreased by 22.66% to 295 million CNY [2]. - The company has distributed a total of 3.673 billion CNY in dividends since its A-share listing, with 687 million CNY distributed in the last three years [3]. - As of September 30, 2025, the number of shareholders increased by 12.87% to 12,900, while the average circulating shares per person decreased by 11.40% to 37,342 shares [2][3].

Group 1 - The core viewpoint of the news is that Sunflower has shown fluctuations in its stock price and financial performance, with a recent increase in stock price but a decline in revenue and profit [1][2]. - As of January 8, Sunflower's stock price increased by 2.03% to 6.52 CNY per share, with a total market capitalization of 8.393 billion CNY [1]. - The company has experienced a net outflow of main funds amounting to 2.1356 million CNY, while large orders showed mixed buying and selling activity [1]. Group 2 - For the period from January to September 2025, Sunflower reported a revenue of 200 million CNY, a year-on-year decrease of 12.09%, and a net profit attributable to shareholders of 1.3062 million CNY, down 53.10% year-on-year [2]. - The company has a total of 133,000 shareholders as of September 30, which is an increase of 112.98% compared to the previous period, while the average circulating shares per person decreased by 53.05% to 9,676 shares [2]. - Since its A-share listing, Sunflower has distributed a total of 204 million CNY in dividends, with no dividends paid in the last three years [3].

Group 1 - The core viewpoint of the news is that Sunflower's stock has experienced a decline in recent trading sessions, with a notable drop of 2.03% on January 7, leading to a market capitalization of 8.058 billion yuan [1] - As of January 7, the stock price is reported at 6.26 yuan per share, with a trading volume of 119 million yuan and a turnover rate of 1.45% [1] - The net outflow of main funds is 21.7157 million yuan, with significant selling pressure observed, as large orders sold 25.2535 million yuan, accounting for 21.29% of the total [1] Group 2 - Year-to-date, Sunflower's stock price has increased by 2.12%, but it has seen a decline of 2.03% over the last five trading days, 16.64% over the last 20 days, and 8.08% over the last 60 days [2] - Sunflower, established on March 21, 2005, and listed on August 27, 2010, focuses on the pharmaceutical sector, primarily in the research, production, and sales of anti-infection, cardiovascular, and digestive system drugs [2] - The company's revenue composition includes 73.44% from raw materials, 26.37% from formulated drugs, and 0.19% from other (non-main) sources [2] Group 3 - Sunflower has distributed a total of 204 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]